Agilvax Announces Strategic Collaboration with Humabs BioMed SA to Develop Targeted Vaccines and Immunotherapies Agilvax, Inc. announced a collaboration with Humabs BioMed that will contribute to the rapid advancement of Agilvax’s ever expanding vaccine and immunotherapy pipeline. Humabs BioMed has established itself as an innovator and leader in the development of human monoclonal antibodies. [Agilvax, Inc.] Press Release Dako, an Agilent Technologies Company, and ONO PHARMACEUTICAL CO., LTD. Announce Collaboration on Development of PD-L1 Companion Diagnostic Test for Investigational Cancer Drug Opdivo® (Nivolumab) Dako and ONO PHARMACEUTICAL CO., LTD. announced a new partnership to develop a potential diagnostic test specifically for use with Opdivo in the treatment of non-small cell lung cancer. [Agilent Technologies, Inc.] Press Release Heat Biologics, Inc. and OncoSec Medical Inc. Announce Collaboration to Evaluate Combination of Immunotherapy Platforms Heat Biologics, Inc. and OncoSec Medical Inc. announced that they have entered into an agreement to evaluate the combination of the immunotherapy approaches developed by each company. [Heat Biologics, Inc.] Press Release UCSF Receives $100 Million Gift to Advance Health Sciences Mission UC San Francisco has received a $100 million gift from visionary philanthropist Charles F. “Chuck” Feeney to support its new Mission Bay hospitals, world-class faculty and students, and research programs focused on the neurosciences and aging. [University of California, San Francisco] Press Release Kaul Foundation Donates $7 Million for UAB Personalized Medicine Institute The Hugh Kaul Foundation has donated $7 million to the University of Alabama at Birmingham (UAB) to establish the Hugh Kaul Personalized Medicine Institute at UAB. [University of Alabama at Birmingham] Press Release Stem Cell ‘Tool’ Grants Given to Five Researchers Five Stanford researchers were awarded grants of between $1 million and $2 million each by the California Institute for Regenerative Medicine at its most recent board meeting. The awards were given through the agency’s “tools and technology” grant program, which encourages researchers to develop new methods and techniques to overcome stumbling blocks in the field. [Stanford Medicine] Press Release Exelixis Announces Acceptance of New Drug Application for Cobimetinib in Combination with Vemurafenib for Treatment of Patients with BRAF V600 Mutation-Positive Advanced Melanoma Exelixis, Inc. announced that the U.S. Food and Drug Administration has accepted for review Genentech’s New Drug Application for cobimetinib in combination with vemurafenib for patients with unresectable or metastatic melanoma harboring a BRAF V600 mutation. [Exelixis, Inc.] Press Release Europe Approves Holoclar®, the First Stem Cell-Based Medicinal Product The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea damage. [Chiesi Farmaceutici S.p.A.] Press Release RepliCel Submits Clinical Trial Application for Its Dermatological Clinical Trial RepliCel Life Sciences Inc. announced the submission of a Clinical Trial Application to the German Competent Authority, the Paul-Ehrlich-Institut, requesting clearance to initiate a Phase I clinical trial investigating the use of RCS-01 to treat patients suffering from aged and UV-damaged skin. [RepliCel Life Sciences Inc.] Press Release Kite Pharma Establishes Manufacturing Capabilities to Support Development and Commercialization of CAR and TCR Cancer Immunotherapy Products Kite Pharma, Inc. announced that it has entered into a lease agreement for a commercial manufacturing facility in El Segundo, California. Kite also recently secured a lease for a clinical manufacturing facility in Santa Monica, California. The two facilities will not only support the planned clinical trials of Kite’s product candidates, but also will prepare Kite for the commercial launch and supply of its lead product candidate, KTE-C19. [Kite Pharma, Inc.] Press Release |